MX355129B - Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes. - Google Patents
Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes.Info
- Publication number
- MX355129B MX355129B MX2014011188A MX2014011188A MX355129B MX 355129 B MX355129 B MX 355129B MX 2014011188 A MX2014011188 A MX 2014011188A MX 2014011188 A MX2014011188 A MX 2014011188A MX 355129 B MX355129 B MX 355129B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- adrenocartical
- compounds
- cell disorders
- treating aberrant
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000001594 aberrant effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 abstract 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 abstract 2
- SDOOGTHIDFZUNM-UHFFFAOYSA-N 1-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(C=2C=CC(=CC=2)N(C)C)CCCC1 SDOOGTHIDFZUNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 abstract 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 abstract 1
- 210000002556 adrenal cortex cell Anatomy 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614269P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/031068 WO2013142214A1 (en) | 2012-03-22 | 2013-03-13 | Compounds and methods for treating aberrant adrenocartical cell disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011188A MX2014011188A (es) | 2015-03-06 |
| MX355129B true MX355129B (es) | 2018-04-06 |
Family
ID=48014328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011188A MX355129B (es) | 2012-03-22 | 2013-03-13 | Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes. |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9107883B2 (enExample) |
| EP (1) | EP2838523A1 (enExample) |
| JP (2) | JP6234987B2 (enExample) |
| CN (2) | CN104302283B (enExample) |
| AU (2) | AU2013235535B2 (enExample) |
| BR (1) | BR112014023517B1 (enExample) |
| CA (1) | CA2867668A1 (enExample) |
| HK (1) | HK1206607A1 (enExample) |
| IN (1) | IN2014DN08604A (enExample) |
| MX (1) | MX355129B (enExample) |
| NZ (1) | NZ630828A (enExample) |
| WO (1) | WO2013142214A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2748238B2 (ja) | 1994-12-20 | 1998-05-06 | 新興機械工業株式会社 | ばね製造装置の足起こし装置 |
| US9107883B2 (en) * | 2012-03-22 | 2015-08-18 | Atterocor, Inc. | Compounds and methods for treating aberrant adrenocartical cell disorders |
| US20150087649A1 (en) * | 2013-09-26 | 2015-03-26 | Atterocor, Inc. | Treating disorders associated with aberrant adrenocortical cell behavior |
| CN107205941A (zh) * | 2014-09-26 | 2017-09-26 | 米伦多治疗公司 | N‑(2,6‑二(1‑甲基乙基)苯基)‑n′‑((1‑(4‑(二甲基氨基)苯基)环戊基)甲基)脲盐酸盐的固体药物形式以及涉及其的组合物、方法和试剂盒 |
| WO2016164476A2 (en) * | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| US20180200209A1 (en) * | 2015-07-10 | 2018-07-19 | Millendo Therapeutics, Inc. | Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| US10231983B1 (en) | 2018-08-22 | 2019-03-19 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US11202787B2 (en) | 2018-07-02 | 2021-12-21 | Corcept Therapeutics, Inc. | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US10780097B2 (en) | 2018-07-02 | 2020-09-22 | Corcept Therapeutics, Inc. | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
| US20220241276A1 (en) * | 2019-06-11 | 2022-08-04 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| NZ577219A (en) * | 2006-12-06 | 2011-11-25 | Smithkline Beecham Corp | Bicyclic compounds and use as antidiabetics |
| WO2009067397A2 (en) * | 2007-11-19 | 2009-05-28 | Ore Pharmaceuticals Inc. | Treatment for solid tumors |
| US9107883B2 (en) * | 2012-03-22 | 2015-08-18 | Atterocor, Inc. | Compounds and methods for treating aberrant adrenocartical cell disorders |
-
2013
- 2013-03-13 US US13/802,047 patent/US9107883B2/en active Active
- 2013-03-13 MX MX2014011188A patent/MX355129B/es active IP Right Grant
- 2013-03-13 CA CA2867668A patent/CA2867668A1/en not_active Abandoned
- 2013-03-13 WO PCT/US2013/031068 patent/WO2013142214A1/en not_active Ceased
- 2013-03-13 IN IN8604DEN2014 patent/IN2014DN08604A/en unknown
- 2013-03-13 BR BR112014023517-1A patent/BR112014023517B1/pt active IP Right Grant
- 2013-03-13 CN CN201380015269.0A patent/CN104302283B/zh active Active
- 2013-03-13 JP JP2015501763A patent/JP6234987B2/ja active Active
- 2013-03-13 NZ NZ630828A patent/NZ630828A/en unknown
- 2013-03-13 HK HK15107166.6A patent/HK1206607A1/xx unknown
- 2013-03-13 CN CN201610595176.5A patent/CN106236741A/zh active Pending
- 2013-03-13 EP EP13712998.7A patent/EP2838523A1/en not_active Withdrawn
- 2013-03-13 AU AU2013235535A patent/AU2013235535B2/en active Active
-
2015
- 2015-07-13 US US14/798,237 patent/US9446010B2/en active Active
-
2016
- 2016-06-01 US US15/170,682 patent/US9877937B2/en active Active
-
2017
- 2017-06-26 JP JP2017124186A patent/JP6317016B2/ja active Active
- 2017-11-17 AU AU2017261632A patent/AU2017261632A1/en not_active Abandoned
- 2017-12-12 US US15/839,647 patent/US20180256524A1/en not_active Abandoned
-
2021
- 2021-06-30 US US17/364,464 patent/US20220160662A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013235535B2 (en) | 2017-09-21 |
| US20160367507A1 (en) | 2016-12-22 |
| HK1206607A1 (en) | 2016-01-15 |
| CN106236741A (zh) | 2016-12-21 |
| US9877937B2 (en) | 2018-01-30 |
| AU2017261632A1 (en) | 2017-12-07 |
| NZ630828A (en) | 2016-10-28 |
| AU2013235535A1 (en) | 2014-10-09 |
| US20220160662A1 (en) | 2022-05-26 |
| US9107883B2 (en) | 2015-08-18 |
| CN104302283B (zh) | 2016-08-24 |
| US9446010B2 (en) | 2016-09-20 |
| CA2867668A1 (en) | 2013-09-26 |
| JP6317016B2 (ja) | 2018-04-25 |
| IN2014DN08604A (enExample) | 2015-05-22 |
| US20160008302A1 (en) | 2016-01-14 |
| JP2017160275A (ja) | 2017-09-14 |
| US20130267550A1 (en) | 2013-10-10 |
| BR112014023517B1 (pt) | 2020-12-01 |
| CN104302283A (zh) | 2015-01-21 |
| US20180256524A1 (en) | 2018-09-13 |
| EP2838523A1 (en) | 2015-02-25 |
| MX2014011188A (es) | 2015-03-06 |
| JP2015510933A (ja) | 2015-04-13 |
| JP6234987B2 (ja) | 2017-11-22 |
| WO2013142214A1 (en) | 2013-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014011188A (es) | Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes. | |
| BR112014015568A8 (pt) | compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia | |
| EA201400161A1 (ru) | Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| HK1198443A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| HK1207069A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| WO2012116237A3 (en) | Heterocyclic compounds and uses thereof | |
| PH12015500719A1 (en) | Gdf-8-inhibitors | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201391682A1 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| MX339002B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| EA201391315A1 (ru) | Гуанидиновое соединение | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| PH12014501157A1 (en) | Pharmaceutical formulations | |
| WO2014081712A3 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| WO2014179154A3 (en) | Novel compounds that are erk inhibitors | |
| EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
| WO2014081714A3 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| NZ630816A (en) | N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors | |
| WO2014081709A3 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride | |
| MX2017003916A (es) | Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: MEDIMMUNE LIMITED |
|
| FG | Grant or registration |